Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HSBC Holdings plc (HSBC) vs Eli Lilly And Co (LLY) Price & Performance

HSBC Holdings plcTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

HSBC Holdings plc vs Eli Lilly And Co — how do they compare? HSBC Holdings plc trades at $104.2 (market cap $353.82B), while Eli Lilly And Co trades at $1,224.5 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 3.1× HSBC Holdings plc's market cap, and HSBC Holdings plc pays the higher dividend (3.63%). Which is the better fit depends on your goals.

HSBCLLY
Market Cap
$353.82B$1.08T
Sector
TechnologyHealth
52-Week High
$107.86$1.24K
52-Week Low
$63.84$639.43
Dividend Yield
3.63%0.57%
Enterprise Value
$1.13T

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HSBC Holdings plc

HSBC's stock trades at $103.88, up 0.54% today, with a bullish technical signal from moving averages and support near $103. Recent Q2 2026 earnings beat expectations with a 7% revenue rise to $19 billion (Defense World, 2026-08-06), and the company announced a $1 billion buyback (WSJ, 2026-08-04). Valuation metrics include a P/E of 14.74 and ROE of 12.44%, reflecting solid profitability.

The outlook is positive due to strong earnings momentum and shareholder returns, but risks include a recent analyst downgrade (Citi to 'neutral' on August 5, 2026) and exposure to Asian market volatility. With 38.1% of analysts rating it a buy, the stock offers growth potential tempered by competitive and regulatory headwinds.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About HSBC Holdings plc

HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.

Read more on HSBC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY